camostat has been researched along with Cirrhosis in 6 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Camostat mesilate (CM), an oral protease inhibitor, has been used clinically for the treatment of chronic pancreatitis in Japan." | 7.73 | Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. ( Arita, Y; Fujimori, N; Gibo, J; Hisano, T; Inoue, M; Ito, T; Kawabe, K; Nawata, H; Oono, T, 2005) |
| "The results of the present study suggest that camostat greatly inhibits pancreatic inflammation and prevents and reverses fibrosis and atrophy of the pancreas in the genetically obese and CCK-1 receptor-deficient OLETF rats." | 7.73 | Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats. ( Jia, D; Otsuki, M; Taguchi, M, 2005) |
| "Camostat has a beneficial effect on pancreatic fibrosis induced by the administration of a SOD inhibitor, which inhibits the proliferation and activation of PSC." | 7.73 | Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats. ( Emori, Y; Ichimura, M; Koide, N; Matsumura, N; Mizushima, T; Ochi, K; Shinji, T; Shirahige, A; Tanimoto, M; Tanioka, H, 2005) |
| "Camostat mesilate (CM), an oral protease inhibitor, has been used clinically for the treatment of chronic pancreatitis in Japan." | 3.73 | Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. ( Arita, Y; Fujimori, N; Gibo, J; Hisano, T; Inoue, M; Ito, T; Kawabe, K; Nawata, H; Oono, T, 2005) |
| "The results of the present study suggest that camostat greatly inhibits pancreatic inflammation and prevents and reverses fibrosis and atrophy of the pancreas in the genetically obese and CCK-1 receptor-deficient OLETF rats." | 3.73 | Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats. ( Jia, D; Otsuki, M; Taguchi, M, 2005) |
| "Camostat has a beneficial effect on pancreatic fibrosis induced by the administration of a SOD inhibitor, which inhibits the proliferation and activation of PSC." | 3.73 | Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats. ( Emori, Y; Ichimura, M; Koide, N; Matsumura, N; Mizushima, T; Ochi, K; Shinji, T; Shirahige, A; Tanimoto, M; Tanioka, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ueda, M | 2 |
| Uchimura, K | 2 |
| Narita, Y | 2 |
| Miyasato, Y | 2 |
| Mizumoto, T | 2 |
| Morinaga, J | 2 |
| Hayata, M | 2 |
| Kakizoe, Y | 2 |
| Adachi, M | 2 |
| Miyoshi, T | 2 |
| Shiraishi, N | 1 |
| Kadowaki, D | 2 |
| Sakai, Y | 2 |
| Mukoyama, M | 2 |
| Kitamura, K | 2 |
| Nakagawa, T | 1 |
| Hirata, S | 1 |
| Gibo, J | 1 |
| Ito, T | 1 |
| Kawabe, K | 1 |
| Hisano, T | 1 |
| Inoue, M | 1 |
| Fujimori, N | 1 |
| Oono, T | 1 |
| Arita, Y | 1 |
| Nawata, H | 1 |
| Jia, D | 1 |
| Taguchi, M | 1 |
| Otsuki, M | 2 |
| Emori, Y | 1 |
| Mizushima, T | 1 |
| Matsumura, N | 1 |
| Ochi, K | 1 |
| Tanioka, H | 1 |
| Shirahige, A | 1 |
| Ichimura, M | 1 |
| Shinji, T | 1 |
| Koide, N | 1 |
| Tanimoto, M | 1 |
| Nagashio, Y | 1 |
1 review available for camostat and Cirrhosis
| Article | Year |
|---|---|
Action of antiproteases on fibrosis in experimental chronic pancreatitis.
Topics: Animals; Disease Models, Animal; Esters; Fibrosis; Gabexate; Guanidines; Pancreatitis, Chronic; Prot | 2007 |
5 other studies available for camostat and Cirrhosis
| Article | Year |
|---|---|
The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Creatinine; Disease Progression; Est | 2015 |
Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazol | 2016 |
Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity.
Topics: Animals; Cell Proliferation; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Dru | 2005 |
Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats.
Topics: Actins; Amylases; Animals; Atrophy; Eating; Esters; Fibrosis; Gabexate; Guanidines; Interleukin-6; L | 2005 |
Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats.
Topics: Administration, Oral; Animals; Disease Models, Animal; Ditiocarb; Drug Administration Schedule; Este | 2005 |